Fortress Biotech, Inc. (FBIO)
| Market Cap | 94.82M |
| Revenue (ttm) | 81.13M |
| Net Income (ttm) | -71.64M |
| Shares Out | 107.41M |
| EPS (ttm) | -0.86 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 7,625,801 |
| Open | 0.940 |
| Previous Close | 0.940 |
| Day's Range | 0.870 - 1.000 |
| 52-Week Range | 0.770 - 3.810 |
| Beta | 2.27 |
| Analysts | Buy |
| Price Target | 9.61 (+988.6%) |
| Earnings Date | May 10, 2022 |
About FBIO
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intra... [Read more...]
Financial Performance
In 2021, FBIO's revenue was $68.79 million, an increase of 50.86% compared to the previous year's $45.60 million. Losses were -$64.70 million, 39.1% more than in 2020.
Financial StatementsAnalyst Forecast
According to 12 analysts, the average rating for FBIO stock is "Buy." The 12-month stock price forecast is 9.61, which is an increase of 988.58% from the latest price.
News
Fortress Biotech Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating Dotinurad for the Treatment of Go...
Dotinurad is a potential best-in-class urate transporter (URAT1) inhibitor in clinical development at Fortress' subsidiary company, UR-1 Therapeutics
Fortress Biotech to Participate in Two Upcoming May 2022 Investor Conferences
MIAMI, May 18, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or mo...
Fortress Biotech (FBIO) Reports Q1 Loss, Tops Revenue Estimates
Fortress Biotech (FBIO) delivered earnings and revenue surprises of 35.71% and 19.27%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
Net revenue for first quarter of 2022 increased 106% period-over-period to $23.9 million, a company quarterly record
Journey Medical Corporation Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
Generated record revenue of $23.3 million for the first quarter of 2022
Journey Medical Corporation to Announce First Quarter 2022 Financial Results on May 10, 2022
Company to host conference call to discuss financial results and provide a corporate update on May 10, 2022 at 4:30 p.m. ET Company to host conference call to discuss financial results and provide a cor...
Fortress Biotech to Present at the 21st Annual Needham Virtual Healthcare Conference
MIAMI, April 07, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or ...
Fortress Biotech Announces Virtual Two-Day R&D Summit Hosted by B. Riley Securities on Tuesday, April 5 and Wednesday...
MIAMI, April 01, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or ...
Fortress Biotech Reports Record 2021 Financial Results and Recent Corporate Highlights
Record 2021: Net revenue of $68.8 million and proceeds from the successful monetization of our investment in Caelum Biosciences of $56.9 million 1
Journey Medical Corporation Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
Generated record net product revenues of $63.1 million for the full year 2021
Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce CUTX-101, Copper Histidinate, Data to be Pre...
Cyprium Therapeutics, a subsidiry of Fortress Biotech, is developing CUTX-101 for the treatment of Menkes disease
Fortress Biotech to Participate in Three March 2022 Investor Conferences
MIAMI, March 09, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or ...
Fortress Biotech Announces Virtual Two-Day Corporate Access Summit Hosted by B. Riley Securities on Tuesday, April 5 ...
MIAMI, March 03, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on efficiently acquiring, developing and commercializing or ...
Fortress Biotech to Participate in the 2nd Annual Winter Wonderland Best Ideas Virtual Investor Conference
MIAMI, Feb. 07, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing p...
Fortress Biotech to Participate in the H.C. Wainwright BioConnect Virtual Conference
MIAMI, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing p...
Fortress Biotech to Ring Nasdaq Stock Market Closing Bell on December 21
NEW YORK, Dec. 21, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing...
Fortress Biotech Announces Initiation of Phase 2 Clinical Trial of Triplex for Adults Co-Infected with HIV and CMV
Helocyte, Inc., a partner company of Fortress Biotech, is developing Triplex for the treatment of cytomegalovirus
Fortress Biotech, Cyprium Therapeutics and Sentynl Therapeutics Announce the Initiation of Rolling Submission of a Ne...
NEW YORK and SOLANA BEACH, Calif., Dec. 07, 2021 (GLOBE NEWSWIRE) -- Cyprium Therapeutics, Inc. (“Cyprium”), a Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”) partner company, with support from its l...
Journey Medical Corporation Announces Closing of Initial Public Offering
SCOTTSDALE, Ariz., Nov. 16, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (NASDAQ: DERM) (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commerc...
Fortress Biotech (FBIO) Reports Q3 Loss, Tops Revenue Estimates
Fortress Biotech (FBIO) delivered earnings and revenue surprises of -225.00% and 14.52%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Fortress Biotech Reports Record Third Quarter 2021 Financial Results and Recent Corporate Highlights
Net revenue for third quarter of 2021 increased 123% year-over-year to $21.1 million, a quarterly record
Journey Medical Corporation Announces Launch of its Initial Public Offering
SCOTTSDALE, Ariz., Nov. 08, 2021 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”), a commercial-stage pharmaceutical company that focuses on the development and commercialization of p...
Fortress Biotech (FBIO) May Report Negative Earnings: Know the Trend Ahead of Q3 Release
Fortress Biotech (FBIO) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Fortress Biotech to Participate in Dawson James Securities' 6th Annual Small Cap Growth Conference
NEW YORK, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (NASDAQ: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring, developing and commercializing or monetizing...
Fortress Biotech and Cyprium Therapeutics Announce Positive Clinical Data for CUTX-101, Copper Histidinate, Presented...
NEW YORK and SOLANA BEACH, Calif., Oct. 13, 2021 /PRNewswire/ -- Cyprium Therapeutics, Inc. ("Cyprium"), a Fortress Biotech, Inc. (Nasdaq: FBIO) ("Fortress") partner company, with support from its licen...